Mindset Pharma Inc.
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
0
Ending by 2030
Feb 2041
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
No maintenance fee falls due on this company's record before Nov 19, 2027.
Recent changes
- 1 of the patents on this record was granted since Aug 21, 2026
- Oct 13 US 12,760,045 3-Pyrrolidine-INDOLE Derivatives as Serotonergic Psychedelic Agents for the Treatment of CNS Disorders
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Showing 1 to 10 of 10
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 11,427,604 | Psilocin Derivatives as Serotonergic Psychedelic Agents for the Treatment of CNS Disorders In force · High confidence | In force | High confidence | |
| US 11,453,689 | 3-Pyrrolidine-INDOLE Derivatives as Serotonergic Psychedelic Agents for the Treatment of CNS Disorders In force · High confidence | In force | High confidence | |
| US 11,591,353 | Psilocin Derivatives as Serotonergic Psychedelic Agents for the Treatment of CNS Disorders In force · Medium confidence | In force | Medium confidence | |
| US 11,597,738 | Psilocin Derivatives as Serotonergic Psychedelic Agents for the Treatment of CNS Disorders In force · High confidence | In force | High confidence | |
| US 12,054,504 | 3-Pyrrolidine-INDOLE Derivatives as Serotonergic Psychedelic Agents for the Treatment of CNS Disorders In force · High confidence | In force | High confidence | |
| US 12,054,505 | Psilocin Derivatives as Serotonergic Psychedelic Agents for the Treatment of CNS Disorders In force · Medium confidence | In force | Medium confidence | |
| US 12,378,266 | Psilocin Derivatives as Serotonergic Psychedelic Agents for the Treatment of CNS Disorders In force · High confidence | In force | High confidence | |
| US 12,760,045 | 3-Pyrrolidine-INDOLE Derivatives as Serotonergic Psychedelic Agents for the Treatment of CNS Disorders In force · Low confidence | In force | Low confidence | |
| US 12,590,060 | Scalable Synthetic Route for Psilocin and Psilocybin In force · High confidence | In force | High confidence | |
| US 12,606,543 | Indole Derivatives as Serotonergic Agents Useful for the Treatment of Disorders Related Thereto In force · High confidence | In force | High confidence |
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
10 pending · 2 abandoned · 1 no status recorded
Showing 1 to 10 of 13, newest filing first. An application has no patent term. A term is computed when and if it grants, and appears on that patent's own page.
| Application | Title | Filed | Status |
|---|---|---|---|
| 19/189,953 | Indole Derivatives as Serotonergic Agents Useful for the Treatment of Disorders Related Thereto | Apr 25, 2025 | Pending |
| 18/982,452 | Psilocin Derivatives as Serotonergic Psychedelic Agents for the Treatment of CNS Disorders | Dec 16, 2024 | Pending |
| 18/857,230 | Indoline Derivatives as Serotonergic Agents Useful for the Treatment of Disorders Related Thereto | Apr 18, 2023 | Pending |
| 18/109,890 | Psilocin Derivatives as Serotonergic Psychedelic Agents for the Treatment of CNS Disorders | Feb 15, 2023 | Abandoned |
| 18/102,359 | Psilocin Derivatives as Serotonergic Psychedelic Agents for the Treatment of CNS Disorders | Jan 27, 2023 | Abandoned |
| 18/683,854 | 3-CYCLOAMINO-INDOLE Compounds as Serotonergic Agents Useful for the Treatment of Disorders Related Thereto | Aug 19, 2022 | Pending |
| 18/683,846 | N-Substituted Indole Derivatives as Serotonergic Agents Useful for the Treatment of Disorders Related Thereto | Aug 19, 2022 | Pending |
| 18/683,842 | Indole Derivatives as Serotonergic Agents Useful for the Treatment of Disorders Related Thereto | Aug 19, 2022 | Pending |
| 18/563,898 | Hallucinogen-Fatty Acid Combination | May 26, 2022 | Pending |
| 18/279,293 | Indole Derivatives as Serotonergic Agents Useful for the Treatment of Disorders Related Thereto | Mar 2, 2022 | Pending |
10 of 13 applications shown.
Pro members see all 13 published applications.